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Abstract
Background: Hyperimmune caprine serum (HICS) is a novel biological therapy with potential benefit for skin in
established diffuse cutaneous systemic sclerosis. Here we report multiplex protein analysis of blood samples from
a placebo-controlled phase II clinical trial and explore mechanisms of action and markers of response.
Methods: Patients were treated with HICS (n = 10) or placebo (n = 10) over 26 weeks, with follow-up open-label
treatment to 52 weeks in 14 patients. Serum or plasma samples at baseline, 26 and 52 weeks were analysed using
multiplex or individual immunoassays for 41 proteins. Patterns of change were analysed by clustering using
Netwalker 1.0, Pearson coefficient and significance analysis of microarrays (SAM) correction.
Results: Cluster analysis, SAM multiplex testing and paired comparison of individual analytes identified proteins
that were upregulated or downregulated during treatment with HICS. There was upregulation of the hypothalamo-
pituitary-adrenal axis after HICS treatment evidenced by increases in α-MSH and ACTH in cases treated with HICS.
Interestingly, significant increase in PIIINP was associated with HICS treatment and improved MRSS suggesting
that this may be a marker of extracellular matrix turnover. Other relevant factors reduced in HICS-treated
patients compared with controls, although not reaching statistical significance included COMP, CCL2, IL6,
TIMP2, Fractalkine and TGFβ1 levels.
Conclusions: Our results suggest mechanisms of action for HICS, including upregulation of α-MSH, that has
been shown to be anti-fibrotic in preclinical models, and possible markers to be included in future trials
targeting skin in diffuse cutaneous systemic sclerosis.
Trial registration: Eudract, No. 2007-003122-24. ClinTrials.gov, No. NCT00769028. Registered 7 October 2008.
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Background
Hyperimmune caprine serum (HICS) has been reported
to have beneficial effects in several disease settings with
potential improvement in several neurological and
inflammatory human diseases [1–5]. The mechanism of
action in these conditions is poorly understood and
likely multifactorial. Proposed pharmacodynamic effects
of HICS include an effect on ion channel function [6–9],
immunosuppression and neuroendocrine modulation
through the hypothalamo-pituitary axis [10].
Recently reported clinical data from a phase II study
in established diffuse cutaneous systemic sclerosis
(dcSSc) suggest possible treatment benefit of HICS for
skin over 26 weeks for active treatment compared with
placebo and meaningful improvement in 50% of cases,
and improvement in modified Rodnan skin score
(MRSS) in an extended dataset including subjects that
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moved from placebo to active treatment after the first
26 weeks [11]. Here we report the effect of treatment on
multiple serum proteins and examine the potential asso-
ciation between changes in analytes and modified
Rodnan skin score in individual study subjects.
In addition to elucidating the effect of HICS, this
systematic study of biologically relevant candidate mo-
lecular markers in a cohort of established dcSSc gives
new insight to a phase of the disease that is associated
with substantial morbidity and mortality, but that has
often been excluded from clinical trials that generally
focus on early diffuse systemic sclerosis (SSc). In this
way we have highlighted the potential benefit of bio-
logical intervention/immunomodulation in established
SSc and also demonstrated that information about skin
treatment may be derived from this population.
Methods
Study cohort and clinical outcomes
This was a placebo-controlled study of 20 patients with
established diffuse cutaneous SSc, defined by disease
duration of at least 36 months from first non-Raynaud’s
symptom. Subjects were randomly allocated 1:1 to active
treatment or placebo. The clinical and demographic
features of the study cohort have been described in de-
tail previously [11]. Of note, three patients withdrew
from the study; one in the HICS group due to cerebral
infarction unrelated to study medication and two in the
placebo group due to progression of disease. After
26 weeks of blinded treatment, all patients were offered
open-label treatment for a further 26 weeks. The blind
of original treatment allocation was maintained to
52 weeks. The flow of subjects for the study is shown in
Additional file 1: Figure S1. For the primary analysis,
baseline and 26-week MRSS were compared and statistical
difference between the active treatment and placebo-treated
cases was compared. Secondary analysis differentiated
responders from non-responders defined by improvement
in skin score by at least 20% of baseline and four MRSS
units. Post hoc analysis of MRSS change included seven
placebo cases that moved to the active treatment and three
cases that continued without medication.
Serum and plasma protein analysis
Blood samples were obtained at baseline, week 0 (pre-
and post-injection of medication), weeks 26 and 52.
Serum and plasma samples were sent frozen to Quest
Diagnostics (Valencia, CA, USA) for single-protein
analysis or Quansys Biosciences (Logan, UT, USA) for
multiplex analysis, as outlined below.
Single-analysis assays were used for analysis of procolla-
gen III N-terminal propeptide (PIIINP), soluble interleukin-
2 receptor (sIL-2R), cartilage oligomeric matrix protein
(COMP), transforming growth factor beta 1 (TGF-β1) and
von Willebrand factor (vWF). vWF samples were plasma
samples and an enzyme-linked immunosorbent assay
(ELISA) (Cat. No. 84793; Aushon Biosystems, Inc., Billerica,
MA, USA). Soluble IL-2R samples were serum samples and
an ELISA (Cat. No. EH2IL2R; Thermo Fisher Scientific,
Waltham, MA, USA). TGF-β1 samples were serum
samples and an ELISA (Cat. No. DB100B; R&D Systems,
Inc., Minneapolis, MN, USA). PIIINP samples were serum
samples and a radioimmunoassay (Cat. No. 06098; Orion
Diagnostica Ltd., Espoo, Finland).
Multiplex serum analysis was performed for αMSH,
ACTH, ANG2, HGF, PDGF-bb, TIMP-1, TIMP-2, VEGF,
FGF basic, Eotaxin, GRO-α, MCP-1, MCP-2, RANTES, I-
309, TARC, IP-10, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12p70, IL-13, IL-15, IL-17, IL-23, IFN-γ, TNF-α,
TNF-β, IFN-α, IFN-β, Fractalkine and PARC by multiplex
analysis. Samples were Quansys Biosciences by Q-Plex
Array™ kits for Human Angiogenesis (No. 150251HU),
Human Chemokine (No. 120251HU), and Human Cyto-
kine (No. 110951HU). Both Fractalkine and PARC were
custom developed from matched pair antibodies available
from R&D Systems. The Q-Plex™ kits used in the sample
testing have undergone extensive validation. Ranges for
each assay were determined by dilutions determining
upper ranges where high-end hook effect and apparent
antibody saturation are avoided and lower ranges that are
above detection limits. Antigen standard curves were per-
formed in duplicate.
Statistical analysis
For each analyte there was an individual comparison of
baseline, 26 and 52 weeks and an integrated multiplex
analysis to look for clusters of change in groups of cyto-
kines that may reflect treatment with HICS or clinical
differences in MRSS occurring during the study period.
Unsupervised and supervised cluster analysis was under-
taken to define baseline differences or changes over 26
and 52 weeks. Differences were compared between treat-
ment groups and also for those with subgrouping strat-
egies at baseline, longitudinally and linked to meaningful
or numerical change in clinical variables. Permutation
analysis was used to compare cytokine levels between
the treatment arm and placebo arm. This was processed
in EXCEL (Microsoft Corp., Redmond, WA, USA) and
analysed using t tests with significance analysis of
microarray (SAM) correction. Normalisation of data
points and hierarchical clustering were performed
using Netwalker 1.0 (http://netwalkersuite.org), and heat
map construction was performed using CIMminer
(https://discover.nci.nih.gov/cimminer/). Scatter plots were
used to explore the association between MRSS and individ-
ual analytes. Baseline and 26-week values were compared
between HICS and control treatment arms in the extended
dataset and changes were also examined in the subset of
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subjects that changed from placebo to HICS at 26 weeks
and for those that received HICS over a total of 52 weeks.
In order to normalise data, the analyte titre was di-
vided by the average titre for all patients at time point
zero, and then log transformed. The normalized data
were expressed as a value that is centred on the mean
level of the analyte across all the samples examined. This
is a well-established and validated method which permits
comparison of multiple proteins in each subject and al-
lows the levels to be compared for different proteins
within the cohort – this both vertical and horizontal
clustering can be achieved for the heat maps. We have
expanded the “Methods” section of the revised manu-
script to explain normalization methods included in our
analysis in more detail. When using SAM analysis, the
cutoff of significance is determined by tuning the param-
eter delta, and then selection based on the fold change
and q value. This highlighted genes that were differen-
tially expressed. A combination of fold change and q
value together with level of statistical significance in uni-
variable comparison for HICS treatment effect compared
with placebo were used to select hallmark upregulated
or downregulated analytes that are included in Table 1
and annotated on heat maps.
Results
Clinical outcome data for modified Rodnan skin score
This manuscript focuses on pre-specified analysis of
multiple serum proteins over 52 weeks. For the first
26 weeks, the enrolled subjects (n = 20) were randomly
assigned to self-administer twice weekly HICS by sub-
cutaneous injection or matched placebo. Following this
period, all subjects were offered the opportunity to re-
ceive 26 weeks of active HICS treatment. Three of the
study cohort did not elect to receive HICS during this
second 26-week period. The primary efficacy end point
for this trial was change in MRSS measured as a con-
tinuous variable and comparing baseline and 26-week
values. The clinical data for the placebo-controlled trial
have been previously reported [11]. Briefly, mean mRSS
fell by 1.4 ± 4.7 units with active treatment but worsened
by 2.1 ± 6.4 units on placebo (p = 0.181, unpaired t test)
when baseline values were compared with 26-week
values. Responder analysis showed that 50% of HICS pa-
tients improved compared to 10% of placebo patients at
26 weeks (p = 0.062). We undertook further analysis of
an extended dataset, comparing placebo patients who
took medication on a compassionate basis after the
double-blind phase of treatment for a further 26 weeks.
Thus, skin score data were available for seven additional
cases treated for 26 weeks with HICS, and from three
cases that chose not to take the drug but that were
observed for a further 26 weeks off treatment. Skin score
data for this extended dataset comprising 13 subjects re-
ceiving placebo or no active therapy with the 17 subjects
that received HICS for 26 weeks confirms statistically
significant difference between active treatment and con-
trols in a post hoc analysis, p = 0.025 (Fig. 1).
Serum and plasma protein analysis
The data for the 26-week placebo-controlled phase of the
study for PIIINP, vWF and sIL2R have been presented pre-
viously [11]. Here we show additional data to week 52 that
confirm the earlier findings (Table 1). For the baseline mea-
surements, there were 20 subjects, at 26 weeks there were
n = 10 receiving placebo and n = 9 receiving HICS due to
one patient discontinuing treatment early in the study.
Fifty-two-week follow-up was on a compassionate basis
Table 1 Representative serum analytes (mean [SD]) for subjects receiving HICS or placebo treatment over 26 weeks
Change during study HICS Change during study placebo HICS versus placebo
Direction of change Basal 26 wk 26 wk versus basal
p value
Basal 26 wk 26 wk versus basal
p value
Fold change q value p value
Sample number n = 10 n = 9 n = 9 n = 10 n = 10 n = 10
UP
α-MSH pg/ml 3.7 [3.6] 31.1 [35.8] 0.0035 1.8 [0.9] 2.2 [1.9] 0.75 299.6 0 0.039
ACTH pg/ml 1.9 [2.4] 27.6 [42.3] 0.0099 1.1 [1.1] 1.0 [0.7] 0.97 176.6 0 0.05
bFGF pg/ml 3.4 [6.5] 21.5 [21.9] 0.0185 21.3 [43.3] 23.6 [51.6] 0.62 65 0 0.15
PIIINP ug/ml 6.9 [3.8] 15.4 [10.1] 0.0002 5.3 [2.7] 5.9 [2.7] 0.62 14.6 20 0.012
DOWN
COMP ng/ml 1.8 [1.1] 1.4 [0.3] 0.055 1.3 [0.5] 1.4 [0.6] 0.7 −3.38 36 0.265
FRACT (CX3CL1) ng/ml 3.7 [6.4 3.3 [6.1] 0.108 1.1 [0.7] 1.0 [0.6] 0.79 −6.1 43 0.318
CCL2 (MCP1) pg/ml 262.3 [101.1] 202.4 [132.0] 0.239 280.6 [133.6] 325.8 [225.9] 0.293 −0.5 36 0.121
TIMP2 ng/ml 13.4 [1.9] 13.0 [1.8] 0.322 13.1 [1.8] 13.9 [2.3] 0.172 −12.6 43 0.1044
TGFβ1 ng/ml 29.4 [7.9] 27.8 [4.3] 0.901 26.4 [4.4] 25.4 [10.4] 0.385 −3.8 43 0.601
Gro-α pg/ml 35.0 [97.2] 10.7 [17.1] 0.076 3.6 [5.5] 10.2 [15.1] 0.939 −2.3 36 0.206
IL6 pg/ml 4.6 [9.7] 1.4 [1.4] 0.309 25.4 [69.5] 30.6 [66.8] 0.128 −0.04 36 0.053
SD standard deviation, HICS hyperimmune caprine serum
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with safety review and so fewer samples were available. For
clarification, the total study cohort was 20 subjects. There
were samples available for assay from n = 7 subjects who
had moved from placebo to HICS, n = 6 subjects continu-
ing HICS treatment and n = 2 subjects who moved from
HICS to no treatment and n = 3 subjects who were in the
placebo arm and chose not to receive HICS from weeks 26
to 52. The flow of patients through the study is illustrated
in the schematic in Additional file 1: Figure S1.
Cluster analysis and heat maps
First, the dataset was examined using cluster analysis
with generation of heat maps to identify differences in
the protein levels for the study cohort at baseline or
26 weeks. Unsupervised analysis of absolute concentra-
tions, scaled and normalized for the purposes of com-
parison, did not show any clear differences for baseline
values (Fig. 2a) whilst the 26-week data are more clus-
tered (Fig. 2b). Changes were examined to explore the
potential effect of HICS on serum protein levels of the
large number of analytes and specifically focus on those
cases that had shown a clinically meaningful improve-
ment in MRSS (responders) compared to those that had
stable or worsening skin score. Unsupervised clustering
was first performed (Additional file 2: Figure S2) and
later supervised analysis (Fig. 3). For these analyses the
primary exploration was for data from the first placebo-
controlled phase of the study, but the extended dataset
including the additional seven patients treated for the
first time with HICS over weeks 26 to 52 are also in-
cluded as a secondary analysis to confirm and extend
the data from the placebo-controlled phase. These are
included in Additional file 3: Figure S3.
To provide a clearer signal of potential serum protein
changes seen in the SSc subjects receiving active treat-
ments in the placebo-controlled phase of the study, a
summary heat map was generated for the placebo-
controlled phase of the study. This demonstrates that
some markers are shared and these may be markers of
clinical change or response. In contrast the signature
comparing HICS and placebo (Additional file 4: Figure
S4) is more likely to be a direct effect of the HICS ad-
ministration and may therefore be a better reflection of
the impact of this novel therapy rather than the clinical
changes occurring in MRSS, that might also provide
insight into potential markers of change in skin severity
that may be independent of treatment effect (Additional
file 4: Figure S4). For the key analytes highlighted in
Table 1 the heat maps are annotated showing that for al-
most all of these the change seen with HICS treatment
compared with placebo was also observed in analysis
based upon the responder status for MRSS.
Statistical analysis of changes in serum proteins
associated with HICS treatment
We next undertook statistical analysis of the whole
dataset using SAM. The strength of this methodology
is that it takes account of the multiple simultaneous
analyses that are performed and corrects the data for
false discovery risk. From this analysis a signature of
proteins up- or downregulated by HICS emerged and
these proteins were then subjected to a more detailed
analysis of change over the 52 weeks of the study.
These proteins are shown in Table 1 together with
the basal and 26-week level, fold change and signifi-
cance assessed by SAM and for individual statistical
analysis of the analytes.
To further demonstrate the changes in proteins that are
upregulated by HICS at 26 weeks, the change in cases that
switched from placebo to active treatment between weeks
26 and 52 treatment effect individual patient data are
plotted in Fig. 4 for key proteins included in Table 1.
Congruity of mean and median values suggests near
Fig. 1 Change in modified Rodnan skin score after 26 weeks of
treatment with hyperimmune caprine serum compared with
placebo or no treatment. In the extended clinical trial dataset
patients received 26 weeks of therapy with HICS or placebo. Seven
subjects that had received placebo were then treated with HICS. For
all subjects there was a 52-week visit and so MRSS between 26 and
52 weeks was available for placebo-treated cases, providing an
extended dataset of 17 subjects receiving HICS and 13 with no
active treatment. Treatment blind for the first 26 weeks was
maintained to week 52. There was statistically significant difference
between these two treatment groups. These data extended the
dataset from the placebo-controlled phase of the study that had
demonstrated a trend of improvement for MRSS and for responder
frequency defined by improvement of at least four skin score units
and 20% of baseline MRSS. The placebo-controlled phase has been
previously described [11]. HICS hyperimmune caprine serum, MRSS
modified Rodnan skin score
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normal distribution and non-parametric assessment and
the results are not significantly different from the methods
included in the current manuscript. As detailed below to
avoid confusion and ensure consistency with the external
statistical analysis included in our final study report, we
prefer to keep the results of parametric testing in this
manuscript. The most significant changes were observed
for αMSH, ACTH, and PIIINP. This demonstrates pat-
terns of change in the extended dataset and in subjects
moving from placebo to active treatment at 26 weeks and
those receiving HICS over a 52-week period. For these
analytes, individual subjects show clear evidence of in-
crease similar to that seen over 24 weeks for actively
treated subjects. Although the small numbers preclude
formal statistical analysis, the data provide support to the
effect seen in the first 26 weeks of the study and in the ex-
tended dataset. Mean and median values of relevant
serum proteins, including COMP, CCL2, IL6, TIMP2,
Fig. 2 Unsupervised hierarchical cluster analysis for multiplex serum proteins at baseline and 26 weeks during the placebo-controlled trial of HICS.
Unsupervised cluster analysis was undertaken to identify any subgroups within the study cohort at baseline based upon the serum levels of
multiple protein analytes as described in text. The same analysis was repeated for serum samples after 26 weeks of treatment with HICS or
placebo. The randomly assigned treatment allocation is shown for each subject. Data for baseline samples are shown in panel a. After 26 weeks
of treatment there were clear changes in the patterns of protein analytes that were spread between the two treatment arms as shown in panel
b. HICS hyperimmune caprine serum
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Fractalkine and TGFβ1were reduced in HICS-treated pa-
tients compared with controls, although not reaching
statistical significance, and are shown in Table 1.
At an individual patient level levels of some analytes, in-
cluding COMP, TGFβ1, αMSH and PIIINP that showed
significant correlation for baseline MRSS confirming pre-
vious published data from other independent studies.
However, there was no correlation between changes in
these analytes and MRSS change during the study at an
individual patient level (data not shown).
Discussion
In this study we demonstrate the value of including
biological analyses exploring potential markers and
mechanisms of treatment effect in clinical trials of novel
potential therapeutics, such as hyperimmune caprine
serum [12]. By including later stage dcSSc we highlight
the feasibility of recruiting this subgroup that may have
some advantages (e.g. clinical homogeneity, acceptability
of requiring no other immunosuppression and acceptabil-
ity of a true placebo control) compared with early-stage
Fig. 3 Supervised analysis for change in serum proteins according to treatment or responder status in the 26-week placebo-controlled trial of
HICS. a Cluster analysis was undertaken for serum analytes after allocation to HICS or placebo during the 26-week parallel-group controlled phase
of the clinical trial to identify any subgroups within the study cohort at baseline based upon the serum levels of multiple protein analytes as
described in text. A pattern of upregulation or downregulation of specific proteins is seen more frequently in cases treated with HICS than
controls. b The same analysis was repeated with subjects allocated to responder or non-responder categories based upon improvement in MRSS
by at least four skin score units and 20% of baseline MRSS. Of the responders 5/6 were in the HICS-treated arm of the study. In this way groups
of proteins that are clustered for similar patterns of change in response to HICS or associated with clinically meaningful improvement in MRSS
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Fig. 4 (See legend on next page.)
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SSc [13]. It is notable that there was progression in the
placebo group in this study that is contrary to recent sug-
gestions that later stage dcSSc is likely to be in a regressive
stage [14]. A potential explanation for this is that immuno-
suppressive treatments were withdrawn in the study
subjects and this may have led to more active skin disease.
Simultaneous measurement of multiple analytes is a
powerful approach that has been applied in cross-
sectional analyses but few longitudinal studies [15, 16].
We identify a molecular signature of HICS response in
SSc and correlate with potential treatment effect that
includes proteins that increase with HICS treatment
compared with untreated cases, especially PIIINP, αMSH
and ACTH, and also proteins that showed trends of
reduction in the HICS-treated subjects. Our findings
suggest potential for development of composite serum
biomarkers for HICS response in SSc and could inform
development of a more generic composite serum bio-
marker for SSc [17–19]. This would complement other
markers that include serum variables and tests of other
available markers such as the enhanced liver fibrosis
(ELF) test [20] and confirm the feasibility of this ap-
proach. Our study has the particular strength of having
longitudinal sampling and simultaneous assessment of
MRSS. The changes observed for HICS treatment are
notable in the context of falling MRSS. For PIIINP, the
changes are unexpected in that there is increase in the
context of improved MRSS both in the overall treatment
cohort for HICS and also in the responder analysis
(Additional file 3: Figure S3). This suggests that PIIINP
may be a marker of extracellular matrix (ECM) remodel-
ing as well as fibrotic burden as discussed below. Other
proteins showing significant change include markers of
activation (αMSH and ACTH) with highly significant in-
crease at 26 weeks suggesting sustained upregulation of
the hypothalamic pituitary axis in response to HICS.
COMP has previously been suggested as a marker of
skin score in scleroderma and so a trend for reduction
in HICS-treated cases but not controls in notable.
Several distinct possible effects of HICS that have
previously been suggested are highly relevant to the
study. First, HICS is likely to have an immunomodula-
tory effect. This may reflect the presence of proteins
and cytokines that affect immune function [21],
including polyclonal immunoglobulin that has previ-
ously been suggested to be beneficial for some aspects
of SSc. A recent retrospective single-centre observa-
tional study of 30 patients with refractive dcSSc receiv-
ing intravenous immunoglobulin (IVIG) showed
significant reduction in MRSS at 24 months, indicating
that it may be an effective adjunctive treatment [22].
To date, only one randomised double-blind trial has
been completed. In this trial, a single 5-day course of
IVIG did not show significant improvement but a
retreatment with a second course showed an im-
provement in skin score [23]. Other recent reports
suggest benefits in gastrointestinal symptoms and
myositis in SSc patients receiving IVIG [24, 25].
One of the most compelling potential anti-fibrotic
mechanisms for HICS is through stimulation of the
hypothalmo-pituitary axis. It is notable that there is con-
siderable evidence that stimulation of MSH pathways
may benefit preclinical animal models of fibrosis and in
vitro studies with human tissue [26–28]. For example,
Bohm et al. described that human dermal fibroblasts ex-
press the MC1 receptor (MC1R) that binds α-MSH with
high affinity and they found that α-MSH suppressed
TGF-β-induced collagen synthesis in vitro [29, 30]. Fur-
thermore, the authors used a bleomycin mouse model to
investigate the effects of α-MSH on skin fibrosis and
found that simultaneous administration of α-MSH with
bleomycin suppressed the effects of bleomycin on HDF.
ACTH was also found to have similar suppressive effects.
α-MSH exerts its effects via a cAMP-driven pathway and
not via Smad 2/3. α-MSH upregulates superoxide dismut-
ase 2 and hemeoxygenase 1, which is protective against
the effects of bleomycin on reactive oxygen species. They
also confirmed the presence of POMC and the MC1R in
affected skin from patients with SSc and dermal fibro-
blasts strongly expressed both POMC and MC1R [31]. In
a recent study MC1-signalling-deficient mice were suscep-
tible to bleomycin-induced fibrosis, whereas wild-type
animals were not [32].
Strengths of this work include prospective definition of
clinical phenotype, collection within the framework of a
double-blind clinical trial and standardised assay method-
ology. Longitudinal sampling of candidate makers and
placebo control data over a clinically meaningful duration
(See figure on previous page.)
Fig. 4 Baseline MRSS correlation and change during treatment with HICS for selected proteins. Individual patient data is shown for key serum
proteins identified as significantly increasing during the 26-week treatment phase of the placebo-controlled trial. The panels compare changes in
the HICS-treated or control extended dataset over 26 weeks that extend the data included in Table 1 for the placebo-controlled phase of the
study. Adjacent plots show the change in the extended 52-week dataset for cases that moved from placebo to HICS at 26 weeks. These findings
confirm the clear pattern of upregulation for PIIINP (a), αMSH (b), and ACTH (c). There is a trend for increase in bFGF (d) whilst the mean levels
for COMP (e), TGFβ1 (f), and MCP1 (g) shows a fall over 26 weeks with HICS treatment. Changes in these key analytes also demonstrate the
heterogeneity of the groups consistent with the heat maps shown above, with some subjects being obvious outliers and only some cases
showing increase in serum levels after moving from placebo to HICS treatment at 26 weeks. HICS hyperimmune caprine serum
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allows more robust interpretation than in cross-sectional
studies. There are also some limitations such as the rela-
tively small number of study subjects in a heterogeneous
disease so that subgroups may be distributed unevenly be-
tween the treatment groups. The need to use different
platforms for some single-factor assays may be a limitation
compared with using the same methods for all analyses. In
addition, conclusions may only apply to late-stage diffuse
cutaneous SSc. It would be useful in future work to extend
this and include other stages and subsets of SSc such as
limited cutaneous disease (lcSSc) or early diffuse SSc. The
effect of previous immunosuppression cannot be reliably
explored in this study but interplay between HICS and
other more conventional immunomodulatory approaches
that are in use as treatment for SSc or its complications
could be addressed in future work.
Conclusions
These findings provide important information about
future potential for SSc molecular markers. They pro-
vide important insight into the potential biological
effects of HICS in SSc and in other medical indications.
The data are hypothesis generating and suggest potential
future therapeutic avenues to explore such as the effect
of HICS in a larger and more diverse clinical cohort, and
possible development of new composite serum markers
that reflect changes in MRSS in clinical trials across the
disease spectrum.
Additional files
Additional file 1: Figure S1. Subject progression in the clinical trials
with serum sample time points. Schematic indicates how 20 subjects
were randomly allocated to active treatment with hyperimmune caprine
serum (HICS) or placebo. One patient withdrew from the HICS arm and
was not available for follow-up. Other subjects were all followed to
52 weeks and at 26 weeks were offered open-label compassionate HICS.
The study blind for 0–26 week treatment was maintained until after 52-
week assessment. Serum and plasma samples were available for weeks 0,
26 and 52. Additional screening blood samples (pre-randomisation) were
available for quality control purposes. (TIF 132 kb)
Additional file 2: Figure S2. Unsupervised hierarchical cluster analysis
for multiplex serum proteins at baseline and 26 weeks for the extended
dataset of 26 weeks treatment with HICS. Unsupervised cluster analysis
was undertaken to identify any subgroups within the extended dataset
of the study cohort at baseline, the end of placebo treatment period, or
at 52 weeks based upon the serum levels of multiple protein analytes as
described in text. This provided a larger sample size by including 17
subjects treated with HICS over 26 weeks and 13 subjects with 26 weeks
of observation on placebo or no active treatment. The same analysis was
repeated for serum samples after 26 weeks of treatment with HICS or
placebo. The randomly assigned treatment allocation is shown for each
subject. Data for baseline samples are shown in panel A together with
treatment allocation. After 26 weeks of treatment there were clear
changes in the patterns of protein analytes that were spread between
the two treatment arms as shown in panel B. (TIF 1373 kb)
Additional file 3: Figure S3. Unsupervised cluster analysis for change
in serum proteins from baseline to 26 weeks comparing treatment with
hyperimmune caprine serum (HICS) with placebo over 26 weeks and in
extended dataset at 52 weeks. (A) Unsupervised cluster analysis of change
in protein level during 26-week treatment phase of placebo-controlled trial
reveals patterns of change that are reflected in the supervised analysis
shown in Fig. 3. Thus, subjects receiving placebo show generally less
treatment effect and those treated with HICS show the patterns consistent
with the summary changes shown above. (B) Unsupervised cluster analysis
is also performed for the extended 52-week dataset that includes subjects
moving from placebo to active treatment (n = 7) in the second 26 weeks
and three cases that have no active treatment and were previously on
placebo. This complements the presentation of data for baseline and
26 weeks presented in Additional file 1: Figure S1 and shows close
congruity for the two 26-week unsupervised heat maps in the
extended dataset. (TIF 1444 kb)
Additional file 4: Figure S4. Average change in serum proteins
comparing treatment with hyperimmune caprine serum (HICS) or
placebo and for MRSS responders versus non-responder at 26 weeks. (A)
Average change in serum protein was calculated for each treatment arm
over 26 weeks and ranked according to fold change average after HICS
treatment. (B) Similar analysis was undertaken for average protein
changes in the subjects showing significant improvement of four skin
score units and 20% of baseline MRSS score during the trial (responders)
or these that did not demonstrate clinical response. These were ranked
for the most increased proteins in responder cases. Key proteins that
emerged as upregulated (red) or downregulated (blue) for HICS treatment,
shown in Fig. 4, are annotated with asterisks. (TIF 761 kb)
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